These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 39355748)
1. Clinical pattern and treatment outcome of cutaneous leishmaniasis patients in Somali region, eastern Ethiopia. Muse AI; Ibrahim MO; Ibrahim MA Skin Health Dis; 2024 Oct; 4(5):e416. PubMed ID: 39355748 [TBL] [Abstract][Full Text] [Related]
2. Clinical pattern and treatment outcome of Cutaneous Leishmaniasis in two hospitals in Bahir Dar, Ethiopia (2017-2021). Tesfa D; Manaye N; De Vries HJ; Van Griensven J; Enbiale W J Infect Dev Ctries; 2022 Aug; 16(8.1):26S-34S. PubMed ID: 36156499 [TBL] [Abstract][Full Text] [Related]
3. Interventions for American cutaneous and mucocutaneous leishmaniasis. Pinart M; Rueda JR; Romero GA; Pinzón-Flórez CE; Osorio-Arango K; Silveira Maia-Elkhoury AN; Reveiz L; Elias VM; Tweed JA Cochrane Database Syst Rev; 2020 Aug; 8(8):CD004834. PubMed ID: 32853410 [TBL] [Abstract][Full Text] [Related]
4. Demographic characteristics and clinical features of patients presenting with different forms of cutaneous leishmaniasis, in Lay Gayint, Northern Ethiopia. Yizengaw E; Gashaw B; Yimer M; Takele Y; Nibret E; Yismaw G; Cruz Cervera E; Ejigu K; Tamiru D; Munshea A; Müller I; Weller R; Cotton JA; Chapman LAC; Kropf P PLoS Negl Trop Dis; 2024 Aug; 18(8):e0012409. PubMed ID: 39146362 [TBL] [Abstract][Full Text] [Related]
5. Progress of Mucocutaneous Leishmaniasis to Drug Nonresponsive Diffuse Cutaneous Leishmaniasis in Ethiopia. A Case Report. Tegegne B; Alemu G Int Med Case Rep J; 2020; 13():551-555. PubMed ID: 33116948 [TBL] [Abstract][Full Text] [Related]
7. Clinical features and treatment response of cutaneous leishmaniasis in North-West Ethiopia. Fikre H; Mohammed R; Atinafu S; van Griensven J; Diro E Trop Med Int Health; 2017 Oct; 22(10):1293-1301. PubMed ID: 28712122 [TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
9. Cutaneous leishmaniasis a neglected tropical disease: community knowledge, attitude and practices in an endemic area, Northwest Ethiopia. Tamiru HF; Mashalla YJ; Mohammed R; Tshweneagae GT BMC Infect Dis; 2019 Oct; 19(1):855. PubMed ID: 31619180 [TBL] [Abstract][Full Text] [Related]
10. Leishmaniasis: recognition and management with a focus on the immunocompromised patient. Choi CM; Lerner EA Am J Clin Dermatol; 2002; 3(2):91-105. PubMed ID: 11893221 [TBL] [Abstract][Full Text] [Related]
11. Knowledge, attitude, and practices towards cutaneous leishmaniasis in referral cases with cutaneous lesions: A cross-sectional survey in remote districts of southern Khyber Pakhtunkhwa, Pakistan. Ahmad S; Obaid MK; Taimur M; Shaheen H; Khan SN; Niaz S; Ali R; Haleem S PLoS One; 2022; 17(5):e0268801. PubMed ID: 35617283 [TBL] [Abstract][Full Text] [Related]
12. Cutaneous, mucocutaneous and visceral leishmaniasis in Sweden from 1996-2016: a retrospective study of clinical characteristics, treatments and outcomes. Glans H; Dotevall L; Söbirk SK; Färnert A; Bradley M BMC Infect Dis; 2018 Dec; 18(1):632. PubMed ID: 30526519 [TBL] [Abstract][Full Text] [Related]
13. New world cutaneous leishmaniasis treated with intralesional injection of pentavalent antimony. Shin JY; Lee YB; Cho BK; Park HJ Ann Dermatol; 2013 Feb; 25(1):80-3. PubMed ID: 23467266 [TBL] [Abstract][Full Text] [Related]
14. Interventions for Old World cutaneous leishmaniasis. Heras-Mosteiro J; Monge-Maillo B; Pinart M; Lopez Pereira P; Reveiz L; Garcia-Carrasco E; Campuzano Cuadrado P; Royuela A; Mendez Roman I; López-Vélez R Cochrane Database Syst Rev; 2017 Dec; 12(12):CD005067. PubMed ID: 29192424 [TBL] [Abstract][Full Text] [Related]
15. PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses. Zijlstra EE PLoS Negl Trop Dis; 2014; 8(11):e3258. PubMed ID: 25412435 [TBL] [Abstract][Full Text] [Related]
16. Mucocutaneous Leishmaniasis/HIV Coinfection Presented as a Diffuse Desquamative Rash. da Silva GA; Sugui D; Nunes RF; de Azevedo K; de Azevedo M; Marques A; Martins C; Ferry FR Case Rep Infect Dis; 2014; 2014():293761. PubMed ID: 25548691 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Immunopathogenesis in Cutaneous Leishmaniasis And Post Kala-azar Dermal Leishmaniasis (PKDL). Volpedo G; Pacheco-Fernandez T; Holcomb EA; Cipriano N; Cox B; Satoskar AR Front Cell Infect Microbiol; 2021; 11():685296. PubMed ID: 34169006 [TBL] [Abstract][Full Text] [Related]
18. Interventions for Old World cutaneous leishmaniasis. Heras-Mosteiro J; Monge-Maillo B; Pinart M; Lopez Pereira P; Reveiz L; Garcia-Carrasco E; Campuzano Cuadrado P; Royuela A; Mendez Roman I; López-Vélez R Cochrane Database Syst Rev; 2017 Nov; 11(11):CD005067. PubMed ID: 29149474 [TBL] [Abstract][Full Text] [Related]
19. Clinical, parasitological and molecular profiles of Cutaneous Leishmaniasis and its associated factors among clinically suspected patients attending Borumeda Hospital, North-East Ethiopia. Bisetegn H; Zeleke AJ; Gadisa E; Shumie G; Damte D; Fenta T; Behaksra S; Bayih AG PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008507. PubMed ID: 32841279 [TBL] [Abstract][Full Text] [Related]
20. Pentavalent Antimonials Combined with Other Therapeutic Alternatives for the Treatment of Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review. Berbert TRN; de Mello TFP; Wolf Nassif P; Mota CA; Silveira AV; Duarte GC; Demarchi IG; Aristides SMA; Lonardoni MVC; Vieira Teixeira JJ; Silveira TGV Dermatol Res Pract; 2018; 2018():9014726. PubMed ID: 30675152 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]